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Abstract 
Background  Long-acting beta2-agonists (LABA) are recommended in asthma therapy, however, not 
all asthma patients respond well to LABA. We performed a systematic review on genetic variants 
associated with LABA response in patients with asthma. 
 
Methods Articles published until April 2017 were searched by two authors using PubMed and 
EMBASE.   Pharmacogenetic studies in patients with asthma and LABA response as an outcome were 
included.  
 
Results   In total, thirty-three studies were included in this systematic review, eight focused on 
children (n=6,051). Nineteen studies were clinical trials, while fourteen were observational studies. 
Studies used different outcomes to define LABA response, e.g. lung function measurements (FEV1, 
PEF, MMEF, FVC), exacerbations, quality of life and asthma symptoms. Most studies (n=30) focussed 
on the ADRB2 gene, encoding the beta2 adrenergic receptor. Thirty studies (n=14,874) addressed 
ADRB2 rs1042713, 7  ADRB2 rs1042714 (n=1,629) and 3 ADRB2 rs1800888 (n=1,892). The association 
of ADRB2 rs1042713 and rs180888 with LABA response heterogeneity was successfully replicated. 
Other variants were only studied in three studies but not replicated. One study focussed on the 
ADCY9 gene. Five studies and a meta-analysis found increased risk of exacerbations in pediatrics 
using LABA carrying one or two A alleles (OR 1.52 [1.17; 1.99]). These results were not confirmed in 
adults.  
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Conclusions  ADRB2 rs1042713 variant is most consistently associated with response to LABA in 
children but not adults. To assess the clinical value of ADRB2 rs1042713 in children with asthma using 
LABA, a randomized clinical trial with well-defined outcomes is needed.  
 
Introduction  
Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment in adults and children. For 
patients with moderate or severe asthma poorly controlled on low-dose ICS current treatment 
guidelines recommend increasing the ICS dosage or adding a long-acting beta-agonist (LABA) 1,2. Both 
are effective therapies for managing asthma by controlling symptoms, improving lung function 
and/or reducing exacerbations in asthmatics3-5.  
 
Nevertheless, there is much variation in how patients respond to LABA. A post-hoc analysis of 85 
patients from two randomized controlled trials (RCTs) showed a variability of ≥ 70% in changes in 
peak expiratory flow in patients receiving salmeterol6. Factors including suboptimal inhalation 
technique, poor adherence, comorbidities, psychosocial factors, and/or continued environmental 
exposure to allergens or air pollution can contribute to this variation7.  
 
Genetic variation can also play an important role in determining LABA response8-12. The contribution 
of genetic factors to observed differences in bronchodilator response is approximately 28.5% for 
short-acting beta-agonist (SABA)13. However, in clinical practice we cannot yet predict LABA response 
14. In 2016, a report by asthma experts commissioned by the FDA, warned for severe asthma 
exacerbations in patients treated with LABA, questioning the safety of LABA in asthmatic adults and 
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children 15-18. A subset of 18% of the asthma patients treated with LABA had increased risk of worse 
asthma outcomes such as lung function decline, severe exacerbations and even death 19-25.  
 
Variation in the ADRB2 gene that codes for the beta2 adrenergic receptor (B2AR) is a usual suspect to 
predict LABA treatment outcomes, due to its central role in the working mechanism of LABA. It 
contains various single nucleotide polymorphisms (SNPs), a single base pair variation that occurs at a 
specific position. In 1992, nine genetic variants in the ADRB2 gene were identified in patients with 
asthma, including rs1042713, rs1042714 and rs180088826. Rs1042713 is known for amino acid 
change (“missense mutation”) in wildtype Gly16Gly by the following variants: Arg16Arg and 
Arg16Gly. Rs1042714 leads to an amino acid change at position 27 and encodes for three genotypes: 
Glu27Gln, Gln27Gln and Glu27Glu.  Both SNPsshowed functional relevance in vitro 13 and were 
further studied to search for associations with LABA response heterogeneity 11,27. There is also some 
evidence for functional relevance of rs180888 at position 164 (Thr164Ile). These three SNPs reduce 
the degree of agonist-promoted downregulation of the B2AR expression and stimulate adenyl cyclase 
activity13. Adenyl cyclase, encoded by the ADCY9 gene, catalyzes the formation of cyclic adenosine 
monophosphate from adenosine triphosphate and is stimulated by the B2AR, being responsible for 
the receptor’s signal transduction. Figure 1 displays various SNPs within the ADRB2 gene and the 
ADCY9 gene. 
 
Because of the large variety in LABA response in asthmatic patients and the suspected genetic 
component responsible for this heterogeneity, we systematically reviewed literature on LABA 
pharmacogenetics. Many papers studied the combined use of ICS and LABA. We will discuss the 
clinical potential of pharmacogenetics of the ADRB2 and the ADCY9 gene in asthma management. 
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Methods 
This systematic review assessed studies on LABA pharmacogenetics in patients with asthma 
published until April 2017. The search was performed using prespecified keywords and Medical 
Subject Headings (MeSH) (table 1). Studies in adults and children were assessed separately. 
Conference abstracts, studies not conducted in humans and papers not written in English were 
excluded. Reporting of this systematic review follows the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement 28. 
 
Table 1. Search term 
pharmacogenetics[MeSH Terms] OR pharmacogenomics[MeSH Terms] OR genetic 
polymorphism[MeSH Terms] OR genetic polymorphisms[MeSH Terms]) OR candidate genes[All 
fields] OR genome wide association studies[All fields]  
AND 
agonists, beta adrenergic[MeSH Terms] OR beta adrenergic agonists[MeSH Terms] OR agents, 
bronchodilator[MeSH Terms]) OR bronchodilators[MeSH Terms] AND long acting[All fields] AND 
(genetic[All fields] OR genes[All fields]) 
 
Abstract sections were screened to determine whether studies described the association of specific 
genetic polymorphisms with the response to LABA by two reviewers (EMAS and NMBO).  
 
After the initial selection, full text papers were analysed and the following data was collected: name 
of the author, year of publication, involved genes and SNPs (rs-numbers), study population, design, 
number of included patients, medication (type, dosage, duration) used, parameters to define 
treatment response and study outcome. We screened review articles for additional research papers. 
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SNPedia 29, PharmGKB 30 and PubMed were used to find the dbSNP reference ID numbers (“rs 
numbers”) when these were not reported. In case of disagreement concerning data extraction, 
consensus between authors was reached. 
 
Quality assessment was performed using the STrengthening the REporting of Genetic Association 
studies (STREGA) checklist (see E2 in this article’s Online Repository) 31,32.  
 
Results 
We identified 151 studies in PubMed and 72 in EMBASE (Figure 2). Three additional studies33-35 were 
identified through review papers 13,36,37. Of all studies, 33 were pharmacogenetics studies that 
studied LABA response heterogeneity in asthma. Fourteen were observational and 19 studies were 
clinical trials (Tables 2-3). Only 33.3% of the identified studies used a prospective genotype-stratified 
design.  All studies were candidate gene studies; none were genome wide association studies 
(GWAS).  
Study outcomes 
Outcomes reported to define LABA response can be divided into three categories: 1) lung function 
measures such as differences in peak expiratory flow (PEF), differences in morning peak expiratory 
flow rate (a.m. PEFR), Forced Vital Capacity (FVC), maximum mid-expiratory flow (MMEF), Forced 
Expiratory Volume in one second (FEV1) and methacholine bronchial challenges 11,12,20,27,33,38-53, 2) 
exacerbations (such as asthma-related emergency department visits, oral corticosteroid prescriptions 
and school absence) 24,33,34,38,44,45,54-58, and 3) patient-centered outcomes (such as asthma control 
questionnaire (ACQ), asthma control test (ACT), night time awakenings, asthma symptoms, rescue 
use of short-acting bronchodilators and quality of life) 11,40-43,45,47,49,52,56.   
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Almost all studies (30 out of 33 studies) identified in our systematic review, investigated ADRB2 
rs1042713 (see reference E1 in this article’s Online Repository). Seven of the 33 studies were 
conducted in children. Nineteen of the 33 studies were trials. Seven studies studied ADRB2 
rs1042714, whereas three studies investigated the ADRB2 rs1800888 SNP (reference E1 and table 2). 
All studies included patients with wide age range. One study focused on ADCY9 SNPs.  
 
ADRB2 
ADRB2 rs1042713 (Arg16Gly) 
Adults 
Lung function outcomes (sixteen studies) 
Five observational studies (n=89 up to 604 participants) did not report an association between lung 
function measurements and different rs1042713 genotypes in patients treated with LABA 33,47,49,51,59.  
 
One RCT and two retrospective analyses of RCTs (total n=446) showed that Arg16Arg patients have 
impaired therapeutic response to LABA when considering lung function as the treatment outcome 
11,12,53. A retrospective pharmacogenetics analysis of the Salmeterol Off CorticoSteroids (SOCS) trial, a 
RCT with 164 well-controlled patients, and the Salmeterol Inhaled Corticosteroids (SLIC) trial, a RCT 
with 175 uncontrolled patients, showed that addition of salmeterol was associated with 51.4 L/min 
lower a.m. PEF in Arg16Arg subjects compared with Gly16Gly patients (p=0.005) 11.  
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In Arg16Arg and Arg16Gly patients there was less protection against bronchoconstriction compared 
to Gly16Gly after the last dose of 1-2 weeks treatment with formoterol or salmeterol 53,60. This was 
measured by methacholine and adenosine monophosphate bronchial challenges. Doses were up 
titrated with 5 minute intervals until a decrease in FEV1 exceeding 20% of baseline was achieved. The 
mean doubling dose/dilution difference between Arg16Arg/Arg16Gly patients and Gly16Gly patients 
in either methacholine or adenosine monophosphate provocative dose/dilution causing a 20% fall in 
FEV1 from baseline (MCh PD20/AMP PC20) of 1.49  (95% CI 0.50-2.48) was shown in a retrospective 
analysis of six RCTs in patients treated with corticosteroids after the last dose of salmeterol or 
formoterol 53.  
 
Furthermore, the LARGE trial - a RCT (n=87) with moderate asthma treated with albuterol and 
salmeterol - showed that methacholine responsiveness improved in Gly16Gly patients treated with 
salmeterol compared to Arg16Arg patients. There were no differences between the genotypes in 
PEFR improvement 12. In another RCT no difference between genotypes in FEV1% predicted (4.2 (-
10.8-19.3), p=0.565, n=64 ) was seen in Arg16Arg vs Arg16Gly patients 43. 
 
Remarkably, two clinical trials (n=237) showed that Arg16Arg patients treated with ICS and LABA had 
more a.m. PEF improvement compared with ICS (LARGE trial, difference [Arg16Arg-Gly16Gly] -0.1 [-
14.4, 14.2], p=0.99, n=87) 12 and improvement of FEV1% (p=0.023 after 8 weeks and p=0.032 after 16 
weeks in 13 Arg16Arg vs. 30 Arg16Gly or Gly16Gly patients) 46. 
 
Six RCTs (n=1001) of which four prospective did not show any interaction between LABA response 
and rs1042713 on lung function outcomes 20,27,40,42,52,53.  
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In a cross-over study 24 Gly16Gly patients received either placebo, leukotriene receptor antagonist 
(LTRA), or LABA as ICS add on treatment (follow-up 6 weeks) 61. Primary outcome was provocative 
dose of methacholine: there was no significant difference in PD20: 1.5-fold [95%CI: 1.1 - 2.2] for LTRA 
vs 1.9-fold [95%CI: 1.2 - 2.9] for LABA, implicating that Gly16Gly patients respond equally to LABA 
and LTRA.   
 
Exacerbations (three studies) 
One observational study (n=108) focused on exacerbations and reported that Arg16Arg patients had 
more exacerbations during daily use of SABA, but not with LABA 33.  
 
Two post hoc RCT analyses (n=2,107 patients) studied the influence on exacerbations despite LABA 
treatment (e.g. time to first severe exacerbation 34 and a worsening asthma event requiring oral or 
parenteral corticosteroids 55). No significant associations were found.  
 
Patient-centered outcomes (five studies) 
Five studies addressed the effect of genotyping on patient-reported outcomes. One observational 
study (n=544) focused on patient-reported asthma outcomes during LABA treatment and reported 
no evidence of an effect of B2AR variation 49.  
 
In a pharmacogenetic RCT, salmeterol was withdrawn in 25 (total n=67) of the included asthma 
patients with an Arg16Arg or Gly16Gly genotype after a six week run in period on 
fluticasone/salmeterol for all patients. Only in the Gly16Gly patients a significant decline of a.m. PEF 
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rate was observed (-14.4 L/s, p=0.06). Nevertheless, LABA discontinuation led to clinically meaningful 
asthma-related quality of life improvement in both groups 39.  
 
Two additional studies (n=106 Arg16Arg and Gly16Gly patients) did not show an association between 
this genetic variation and variation in LABA response measured by symptom scores 40 and ACQ 42. A 
post-hoc RCT analysis (n=183 patients receiving LABA and ICS) did not discover associations with 
night time awakenings 52.  
 
Paediatric studies  
Most studies used exacerbations and patient-centered outcomes, but not lung function as main 
outcome measures. 
 
Exacerbations (six studies) 
In total 2,666 children were studied in LABA pharmacogenetic studies with exacerbations as an 
outcome. Of these studies, five found increased risk of exacerbations 44,45,57,58 in Arg16Arg patients 
treated with LABA. Four were included in a meta-analysis 62.  
 
The first paediatric studies showing an effect of Arg16 on LABA response heterogeneity were 
performed within BREATHE 45,57,58. The association of carrying this genetic variant and LABA response 
was studied (n=546, 3 to 22 years) in patients treated with albuterol, salmeterol and ICS (37). An 
increased hazard of exacerbations over the previous six months was found in Arg16Arg patients 
treated with salmeterol compared with Gly16Gly patients (OR 3.40, 95%CI: 1.19-3.53, p=0.010).  
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Three years later a study (n=1,182) in BREATHE was published 57. Compared to Gly16Gly patients, 
Arg16Arg patients had an OR for asthma exacerbation response of 2.70 [1.46-4.99], p=0.002.  
 
An observational study was conducted (n=597) with reported regular use of asthma medication 
(double dose ICS or ICS and LABA) participating in the PACMAN cohort 56. Increased risk of oral 
corticosteroid use was found in Arg16Arg patients treated with LABA and ICS compared to the ICS-
only group: OR 14.9 [95%CI: 1.59-140.1]. 
 
In contrast, a population-based prospective cohort study (n=97 treated with fluticasone propionate 
and salmeterol), did not find effect of ADRB2 genotype on LABA treatment outcomes 44. There was 
no difference in risk of asthma exacerbations or lung function decline between Arg16Arg and 
Gly16Gly or Gly16Arg patients. Furthermore, a three-treatment, three-period crossover RCT (n=182, 
6-17 years) showed that Arg16Gly did not predict probability of best response to ICS, ICS plus LABA 
or ICS plus montelukast defined by acute asthma exacerbations, number of asthma-control days and 
FEV1 (p=0.49) (5).  
In 2016, a meta-analysis focusing on the association between ADRB2 rs1042713 and LABA response 
was performed 54 in five childhood asthma cohorts (4,226 children and young adults) participating in 
the Pharmacogenomics in Childhood Asthma (PiCA) Consortium 63: the previously published BREATHE 
(UK) 45,57,58 and PACMAN studies (NL) 56, as well as GALA II (USA), PAGES (UK) and PASS (UK). LABA use 
was associated with increased risk of asthma exacerbations carrying one or two Arg alleles at 
rs1042713: OR 1.52 per Arg allele [1.17; 1.99]. The risk was highest in GALA II and lowest in PASS. 
GALA II involved Latino Americans and PASS included Africans and Caucasians, but excluded Asians. 
There was no association between effect size for exacerbation risk and characteristics of the 
populations.  
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Patient centered outcomes (one study) 
Arg16Arg children (n=62, 5-18 years) selected from BREATHE were randomized over ICS+montelukast 
or ICS+LABA+placebo in a RCT. Reported asthma-related school absences were reduced in children 
treated with montelukast compared with salmeterol (difference in score: -0.40 [95%CI: -0.22 to -
0.58]) 45. Salbutamol use was also reduced in the montelukast group compared to the salmeterol 
group (difference: -0.47 [95%CI: -0.16 to -0.79]).  
 
ADRB2 Arg16 heterozygotes (three studies) 
Only three studies described results for heterozygous patients. FEV1 decline was described for each 
Arg allele irrespective of ICS or LABA use (n=604 adults): 7.7±2.5 mL/year 47. The earlier discussed 
paper (n=1,182, 3-22 years) showed increased risk of exacerbations in Arg16Gly compared to 
Gly16Gly patients (OR: 1.63 [95%CI: 1.02-2.60]) 57. The previously mentioned meta-analysis showed 
an increased OR for exacerbations 1.52 [1.17-1.99] (p=0.0021) for each copy of the A allele in 637 
children treated with ICS+LABA therapy, but no increased risk was seen in patients treated with ICS 
or ICS+LTRA or ICS+LTRA+LABA 54.  
 
Overall, there is a difference between children and adults regarding the influence of the rs1042713 
genotype on LABA response. Most studies in adults did not show a difference in risk of exacerbations 
and in LABA response, however, Arg16Arg and Arg16Gly children had less response to LABA add on 
treatment and more exacerbations compared to Gly16Gly patients. Furthermore, Arg16Arg children 
may have higher risk of exacerbations when treated with LABA compared to Gly16 children 45,54.  
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ADRB2 rs1042714 (Glu27Gln) 
One study in BREATHE described tight linkage disequilibrium by not observing any individuals with 
the compound diplotype of Arg16Arg and Glu27Glu58.  
 
Adults (five studies) 
A RCT (n=87) described that LABA response in the context of this genetic variant was age-dependent. 
Asthmatic 27Gln patients (≤50 years) had better response to LABA with low and moderate doses of 
ICS, while 27Glu patients (> 50 years) were more likely to respond to LABA and ICS combination 
therapy 41. Younger 27Gln carriers responded better to ICS and LABA, this may be used in 
personalized asthma treatment. On the other hand, three RCTs comparing Gln27Glu, Gln27Gln and 
Glu27Glu (n=791) did not find any associations focusing on lung function outcomes such as FEV1, 
FEV1% predicted, FEV1/FEC ratio and a.m. PEF 43,49,52. 
 
A post-hoc analysis of a RCT with 183 patients focused on exacerbations and did not find association 
between rs1042714 and LABA response 52. Two studies, of which one prospective, did not find a 
pharmacogenetic effect of rs1042714 in LABA response heterogeneity (n=883) with asthma symptom 
scores as their main outcome 11,49,52.  
 
Paediatrics (two studies) 
Two studies (n= 643) focused on exacerbations and rs1042714 variance in LABA response 
heterogeneity, but did not find any differences 44,58.  
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To summarize results for ADRB2 rs1042714, one adult study (n=87) showed an age-dependent effect. 
The other five other studies did not report any influence of variety in LABA response by rs1042714, 
but did not assess the effect of age.  
 
ADRB2 rs1800888 (three studies) 
One observational study reported that non-Hispanic white adults with asthma treated with LABA 
carrying Thr164Ile (n=18) needed more urgent outpatient health-care or emergency department 
visits for asthma exacerbations during the past year compared to Thr164Thr patients (n=18 Thr164Ile 
vs n=553 Thr164Thr; 2.6 [SD=3.5] vs. 1.1 [2.1] visits, p<0.0001). Thr164Ile was associated with 
reduced urgent visits in non-Hispanic, white patients not treated with LABA (nine Thr164Ile vs 216 
Thr164 patients; 0.1 [0.2] vs 0.5 [1.6] visits, p=0.01). The replication cohort showed similar results in 
favor of these outcomes 64. 
 
Two RCTs (a post-hoc and a genotype-stratified analysis, n=544 and 183 adults) studied lung 
function, but did not find any association between Thr164Ile and poor LABA response 49,52.  
 
To conclude, only adults were studied. It remains inconclusive whether ADRB2 rs180888 is associated 
with LABA response. During LABA treatment, the relationship between lung function and rs1800888 
seems to be different compared to the relationship between rs1800888 and exacerbations. Future 
research on Thr164Ile and LABA response should include outcome measures in all previously 
described outcome categories. 
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Genetic association and candidate gene studies with other ADRB2 SNPs (three studies) 
Various other SNPs within the ADRB2 gene were investigated in adults (Tables 2-3), but there was no 
evidence for a pharmacogenetic effect on lung function response to salmeterol 49. In contrast, a 
candidate-gene study showed that in 186 LABA-treated African Americans a 25 bp insertion-deletion 
at nucleotide -376 relative to the ATG start site (the -376 in –del variant) was associated with 
increased asthma-related hospital admissions: OR 13.43 [2.02-265.42], p=0.006 64.  
 
ADCY9 (one study) 
The ADCY9 gene has been positively associated with LABA response in a post-hoc analysis of a 12-
week clinical trial (n=86 Korean adults) using lung function to measure LABA response. After a two-
week ‘run-in’ period, patients received budesonide and formoterol. The following SNPs in ADCY9 
were studied: rs2230739 (Ile772Met), rs1045475, rs1045476, rs879619 and rs710893. Two were 
associated with LABA response. The ADCY9 rs2230739 Ile772Met was described to be associated 
with improvement in predicted FEV1: 0.7 ± 9.6 after 8 weeks of treatment (p=0.03). The ADCY9 
rs879619 C/T polymorphism was associated with differences in percent change in MMEF: 7.5 ± 15 
(p=0.016) after 8 weeks of treatment. Nevertheless, these changes are not clinically relevant and did 
not remain significant after a 12 week follow-up46.  
 
This study also described a gene-gene interaction of ADCY9 Ile772Met and ADRB2 Arg16Gly. There 
was significant FEV1% improvement (8.4 ± 7.5%) in the CT or CC Ile772Met – A/G Gly16Gly genotype 
combination compared to the TT Ile772Met – A/G or G/G genotype combination. This interaction 
showed additive effect on bronchodilator response to LABA in combination therapy 46. These findings 
have not been further studied.  
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Quality of reporting  
Results of the quality reporting assessment can be found in Supplementary information 1. 18 (54.5%) 
studies published according to the STREGA guidelines. Restriction of analysis to high quality papers 
did not change initial conclusions. 
 
Discussion 
This systematic review showed that most LABA pharmacogenetics studies focussed on variants in the 
ADRB2 gene and that findings differ between adults and children. One variant within that gene and 
the rs1042713 variant is expected to be associated with LABA altered response in children, but not in 
adults. In children exacerbations were used as main outcome, whilst in adults mainly lung function. 
Only three studies measured exacerbations as an outcome in adults, but none found association 
between rs1042713 and LABA response.  
 
Compared to adults, contribution of genetics to variability in LABA response is larger in children with 
asthma. This could be due to the different phenotype in children, which is often characterized by less 
airway wall rigidity, more atopy and shorter exposure to chronic airway inflammation 65. Also 
shortened response and airway smooth muscle relaxation time in children and faster maximal 
bronchoconstriction post-exercise are characteristics that differ from adults 66. These differences 
underline that children should not just be considered ‘small adults’ 67. Another reason for not 
observing an effect in adults may be that studies with children have considerable higher numbers 
compared to the studies conducted in adults. The effect size of ADRB2 SNP effects is small as is the 
sample size in adults.  
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In relation to LABA response, it is important to consider that LABA can cause desensitization or 
downregulation of the B2AR in human bronchial smooth muscle tissue over time. This may result in a 
decrease of receptors or an increase of receptor degradation 44. Desensitization and downregulation 
result in reduced bronchoprotective effects of LABA 65. Previous studies showed bronchoprotective 
subsensitivity for LABAs in Arg16 homozygous adults 44,47,53. This effect is also seen in children, but 
has not been studied in relation to their genotypes 68. ICS can play a role: ICS can reverse functional 
desensitization of B2ARs and increase receptor expression and density 66,69,70. Loss of 
bronchoprotection due to regularly inhaled LABA seems to reverse only with high dose ICS 71,72. Only 
two of the included studies mentioned this mechanism in their discussion as a possible reason for not 
measuring any effects 12,44. The LARGE trial showed no differences between genotypes in PEFR 
response, but methacholine responsiveness improved in homozygous Gly27 patients treated with 
salmeterol compared to Arg16 homozygotes. This finding could highlight differences in 
desensitization of bronchoprotective effects between polymorphic variants 12. 
 
Few studies focussed on the additive or synergic effect of multiple variants on LABA response. Only 
four studies (study populations 97 to 639 patients) focussed on ADRB2 haplotypes 44,48,49,52. This did 
not lead into new insights. Gene-gene interactions with the Arg16Gly were only shown in two 
studies. A gene-gene interaction was described in a Korean study: FEV1% improvement in the C/T or 
C/C Ile772Met and A/A genotype of the ADRB2 Arg16Gly was found, but not in the T/T Ile772Met 
and A/G or G/G Arg16Gly genotype combination 46. The construction of a genetic risk score might 
provide more information than focussing on a single SNP 73.  
 
In Caucasian populations, promotor polymorphisms and rs1042714 Glu27Gln were in complete 
linkage disequilibrium with the Arg16 variant 58,74. Glu27Gln haplotypes were confounded by tight 
disequilibrium with Arg16 variants, and therefore independent effects were difficult to assess. On the 
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contrary, a haplotype analysis study identified 12 haplotypes in the ADRB2 gene and described that 
no individual SNP could be a surrogate marker for their haplotype findings. This may indicate that 
unique interactions of the SNPs within a haplotype will affect biologic and therapeutic phenotypes 
and that prediction with individual SNPs will be insufficient to use in pharmacogenetics.74 
Furthermore, other variants within the ADRB2 gene do not show consistent associations with LABA 
response. Six other ADRB2 SNPs have been studied, and their results did not show reproducible 
associations, however large scale and comprehensive analysis is required to clarify the full genetic 
architecture of this locus.   
 
As can be expected based on the mechanism of action of SABA and LABA, there is overlap in genetic 
risk factors for poor SABA/LABA response in ADRB2 75 and ADCY9 76 genes. In contrast to LABA, SABA 
GWAS data are available. Genes only associated with SABA response heterogeneity in GWAS studies, 
but not found in LABA candidate gene studies are: SLC24A4 76, SPATS2L (replicated) 77, SPATA13 and 
its associated antisense RNA 78, intronic SNPs in COL22A1 and CLOCK genes 79, ASB3 75 and FGF14 80. 
The SABA GWAS used change in lung function as outcome. These results are specific for SABA 
response heterogeneity associations, as patients were not treated with asthma co-medication. When 
studying LABA, interference with genes associated with ICS or LTRA response can occur and the 
effect of LABA can be influenced by ICS 81. Genes associated with SABA response heterogeneity might 
influence LABA response heterogeneity as well.   
 
It has to be mentioned that ethnic patient stratification within studies was not reported. The Arg16 
and Gln27 are common, but vary within ethnicities. The reported allele frequency for the Arg16 allele 
is 0.39, 0.52 and 0.55 in European, African and East Asian healthy populations respectively 82. Gln27 
has an allele frequency of 0.59, 0.82 and 0.93 in European, African and East Asian healthy 
populations respectively, it is a very common allele 83. On the contrary, Thr164Ile is very rare (minor 
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allele frequencies: 0.02, 0.00 and 0.00 in European, African and East Asian healthy controls, 
respectively) 84. 
 
Furthermore, reporting ethnicity is important since unrecognized population stratification can lead to 
false positive or false negative associations 85. For example, a rare insertion in African Americans 
treated with LABA leads to increased exacerbations 64. We recommend new studies to report 
whether genetic associations with LABA were related to specific ethnicities. A lack of power can also 
lead to false negative association. More than half of the included studies did not perform power 
calculations. As effect sizes in LABA response are small, a large sample size to include enough cases 
and controls is necessary to create clinically translatable results.  
 
Furthermore, studies focussing on LABA pharmacogenetics are difficult to compare due to variability 
in outcomes studied. In addition, different dimensions of response might be associated with different 
genetic profiles. Use of the ACQ for example, may result in different findings than exacerbations, as 
children with uncontrolled symptoms may not be the same as children with (sudden) severe 
exacerbations 86.  
 
Most limitations of the included studies may be due to study design. Future research in this field 
should focus on prospective observational studies and RCTs focussing on genes shown to influence 
response heterogeneity and GWAS. These studies should focus on a variety of outcome measures, 
preferably including patient-centered outcomes as well as exacerbations and lung function 
measurements. It would even be more beneficial to standardize response definitions in 
pharmacogenetics or to define composite scores.  
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In order to move from association to implementation in clinical practice, clinical validity of identified 
genetic variants should be assessed. To provide indications about clinical validity, measures such as 
number needed to genotype, population attributable fraction (proportion of adverse events that can 
potentially be eliminated if patients carrying the genetic variant receive different treatments), 
positive and negative predictive value (probability of an adverse event when the genetic variant is 
present, and probability of no adverse events when the genetic variant is absent) and number 
needed to treat should be presented 87. The identified pharmacogenetics studies only provide 
association measures such as OR and RR. This makes interpretation of the results for use in clinical 
practice difficult.  
 
We used STREGA to assess the quality of the studies used in this systematic review. With this quality 
reporting checklist, we objectively assessed quality of reporting in genetic research reports. We 
recommend future researchers in this field to follow the latest quality guidelines to support 
validation and replication. Furthermore, in most studies, patients heterozygous for the associated 
variant were not included; making it more difficult to translate outcomes into treatment guidelines 
for all asthmatics.  
 
In conclusion, there is considerable variability in pharmacogenetic LABA studies due to differences in 
study design and characteristics of included patients. Environmental conditions, such as 
socioeconomic factors (income, education), ethnic genetic variants, environmental allergen 
exposure, psychosocial stressors, behavioural risk factors (smoking, obesity), poor medication 
adherence, and lack of access to medicines or evidence-based care, can influence gene expression88-
90. ADRB2 rs1042713 has been shown to influence LABA response in children in observational studies.  
There is need for a RCT to evaluate the impact of ADRB2 rs1042713 genotyping in children before 
starting a LABA 91. To identify other SNPs involved in LABA response heterogeneity, larger studies 
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with well-defined, comparable outcomes and proper analyses (for example a GWAS including gene-
gene and gene-environment interactions 92) are needed. 
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Table 2. Included studies without the ADRB2 rs1042713 SNP
Study Gene and SNPs Study population Design Medication Definition of the response Study outcome 
Ortega et 
al. 2014 64 
ADRB2 (5q32), 
6 rare variants: 
rs148459047: 
(C/A), 
rs33973603: 
(A/G), 
rs1800888: 
(T/C) , 
rs3729943: 
(C/G), 
Leu342Pro: 
(T/C), (-376 in -
del)  
1165 African 
americans, age 30 
(14); non-Hispanic 
whites, age 37 (16) 
and Puerto Rican 
asthma patients, 
age 38 (19) 
candidate-
gene study 
LABA Asthma related hopitsal 
admissions  
Patients with the rare ADRB2 variant: Thr164Ile 
and (-376 in -del) had increased asthma-related 
hospital admissions compared to patients with 
the common allele.  
       
Ambrose 
et al. 2012 
93 
ADRB2 (5q32) 
poly-C 
genotype: all 
variation in the 
poly-C region 
(+1266 to 
+1278)  
2250 Asthma 
patients (mean age 
38 (17)); 73 
Caucasian of 
European descent 
(n=1614), 7% Asian 
(n=156), 1% African 
(n=21) and 19% 
were of mixed or 
other race (n=434) 
Randomised 
controlled 
trial 
budesonide/formoterol 
or 
fluticasone/salmeterol 
The relation between poly-C 
repeat polymorphism and 
number of severe asthma 
exacerbations and changes in 
pulmonary function 
measurements (FEV1 and 
a.m. PEF), total symptom 
scores, rescue medication use 
and night time awakenings 
The extensive sequence diversity present in de 
poly-C repeat region of the ADRB2 3'UTR did not 
predict therapeutic response to ICS/LABA therapy 
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